


PHARMACEUTICAL 2023

ATAI Life Sciences N.V. Rank 129 of 446









ATAI Life Sciences N.V. Rank 129 of 446



The relative strengths and weaknesses of ATAI Life Sciences N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATAI Life Sciences N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of ATAI Life Sciences N.V. is the variable Net Income, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 128% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	287,145
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,897
Liabilities, Non-Current	3,708
Other Assets	17,368
Other Compr. Net Income	-8,384
Other Expenses	6,586
Other Liabilities	16,070
Other Net Income	-6,401
Other Revenues	233
Property and Equipment	928
Research and Development	74,313
Selling, General and Administrative Expense	70,350

Output Variable	Value in 1000 USD
Assets	305,441
Liabilities	39,675
Expenses	151,249
Revenues	233
Stockholders Equity	265,766
Net Income	-157,417
Comprehensive Net Income	-161,609
Economic Capital Ratio	171%

